Since 1980, calcium channel blockers (CCBs) have been used effectively to lower high blood pressure (HBP). Flekestein proposed that CCBs could be used to avoid calcium deposition on the arterial wall, one of the main components of atherosclerosis. This is also called
Introduction
Since the early 1980s 1 different kinds of calcium channel antagonists or calcium channel blockers (CCBs) have been widely used as an effective group of drugs to lower high blood pressure (HBP). These agents have been used for long periods of time without major secondary effects. Furthermore, some of the CCBs also have anti-arrhythmic properties, ie, verapamil. 2 
Flekestein
3,4 pointed out the relationship between calcium (Ca) and the arterial wall in the atherosclerotic process. He showed the presence of Ca deposits in a larger proportion in comparison with lipid deposition in using atherosclerotic tissue. He also found evidence of the relationship of these deposits with age and its contribution to the arteriosclerotic process (hardening of the arteries). This process occurs when calcium reacts with elastin. This is called ectopic calcium, 5 because it is out of its natural place, ie, calcium should be in bones or teeth but not in the arteries. 6 The same process occurs with calcification of porcine aortic valves when used as prostheses. 7 Considering these findings, Flekestein proposed the use of the CCBs to avoid the Ca depositions in the arterial wall, particularly in those areas prone to develop atherosclerosis (coronaries, aorta, etc). Calcium is deposited in the arterial wall as calcium salts mostly hydroxiapadite. On the other hand, CCBs act on ionic calcium (Ca ++ ) at the level of calcium voltage-dependent channels (L channel). These channels are found in numerous cells like the cardiac and smooth muscle cells, but not in endothelial cells or platelets. However, endothelial cells and platelets may have functions related to ionic Ca. 8 CCBs may have some actions in those cells via calcium and phospholipid protein kinase (PKC). Most importantly, although CCBs work in avoiding calcium deposition (salts), some other mechanisms may also exist. They will be reviewed later.
Plasma calcium reaches 10 mg or 5 meq per litre, from which 2.3 meq are Ca ++ . This Ca ++ is in balance with disphophate, H 3 PO −/− . When this balance is broken, exceeding the so-called multiplying point, calcium precipitates in salts. In many cases this precipitation can take place in the arterial wall. However, the relationship between the lipid components of the arterial wall and Ca precipitation as a contributor to atherosclerotic plaque is not clear and remains to be elucidated. 10 Several studies have shown that CCBs have an anti-atherosclerotic action not only in animals but also in humans. 11, 12 That action may occur in 'pleiotropic effects'. Although these anti-atherosclerotic effects have been in many instances well documented, the controversy remains. Some studies (INTACT, MIDAS) have shown that patients treated with CCBs had an increased incidence of cardiovascular events against those in the placebo group. 13 Some authors suggested that certain CCBs, principally short-acting dihydropyridines, could be proischaemic.
14 Recently, the Framingham Heart Study could not identify this deleterious effect in men and women with hypertension under CCBs therapy.
15
Available calcium channel blockers: current classification Table 1 shows all the CCBs classifications. 16, 17 Dihydropyridines are the most used agents in the atherosclerotic process, particularly nifedipine (short action), amlodipine (intermediate action), isradipine, nicardipine, verapamil which is a phenilalkilamine, and diltiazem, a benzothazepine.
Where is Ca
؉؉ required?: how calcium can promove atherosclerosis 18 All these processes are biological in nature. On the other hand, calcium is considered to be a main actor in pathological conditions as atherosclerosis. Briefly, it is thought that calcium may be present in the atheroma formation amongst other processes through: (a) increasing endothelial permeability; (b) facilitating cholesterol deposition; (c) inducing platelet deposition with endothelial injury; (d) promoting smooth muscle cell migration; (e) provoking lipoprotein's endocitosis; and (f) producing cell calcification.
11
Calcium channel blockers and antiatherosclerotics properties Flekestein 3 suggested the use of CCBs to block all those actions mentioned above. Since then, research has tried to elucidate this issue. Jackson et al 19 reported a summary of 44 trials in experimental models (rats and rabbits). Thirty-one of those studies showed a decrease in atherosclerotic plaque formation in the experimental animal vs the control group. Further analysis proposed that CCBs action may be on cell proliferation with a reduction of the thymidine incorporation to DNA. 20 Probably the CCBs real actions could be attributed to some pleiotropic mechanisms out of the L-channel blockers itself. 21 CCBs could act blocking the intracellular Ca ++ overcharge and inhibiting smooth muscle cell proliferation. Also CCBs can avoid macrophages and neutrophils chemotactic properties, stimulating lowdensity lipoprotein (LDL) receptors. In addition, CCBs can improve receptor-mediated lipoprotein captation, inhibiting cholesterol synthesis and promoting hydrolysis of cholesterol esters. Finally, CCBs may decrease very low-density lipoprotein (VLDL) secretion by hepatocytes. 12, 18, 22 The following mechanisms could also be considered as CCBs pleiotropic effects: (a) antagonism of pharmacologic receptors, particularly on phenilalkilamines and benzotiazepines with specific action on muscarinic, opiate and serotoninic receptors; (b) antagonism of calmodulin; (c) sodium (Na) voltage-dependent channel blockage; (d) modulation of the ratio Na/K ATPase and the transportation system of Ca AtPase; (e) adenosine
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(dihydropyridine) transportation; 23 (f) inhibition of growth factors in cultured tissue; (g) calcium channel non-dependent platelet function; (h) LDL-receptor bio-synthesis (dehydropyridine); (i) intercellular interference on cholesterol bio-synthesis; (j) intervention with cholesterol cellular homeostasis; and (k) interaction with cellular Ca homeostasis.
24,25
Also, it is known that amlodipine prevents lipidic oxidation, diminishing smooth muscle cell proliferation.
26,27 Furthermore, statin may have a synergistic association with a CCBs to lower the atherosclerosis process. 28 Felodipine has been shown to diminish adhesion of mononuclear cells and lipidic deposition. 29 Other additional conditions of the CCBs should also be considered: (a) improvement of endothelial membrane function (block the Ca ++ entry in inadequate quantities); 30 (b) reduction of arterial wall stress; (c) inhibition of platelet-wall interaction; (d) inhibition of smooth muscle cell migration; (e) reduction of LDL captation; and (f) anti-aggregant effects by calmodulin, cyclic AMP and phosphodiesterase inhibition.
31

Human investigations, trials, failures and the future
Several in vivo studies have been carried out to test the hypothesis that CCBs may have anti-atherosclerotic properties, promoting a better cardiovascular function. 32 For example, the action of a CCBs over nitric oxide (NO) availability and the inhibition of free radicals induced by oxidized LDL have already been tested in humans.
33,34 Table 2 shows two finished studies and six still in progress. After analysing these studies, it is clear that the CCBs controversies have not been elucidated yet. 35, 36 For example, the INTACT study 31, 37, 38 showed a reduced atherosclerotic plaque progression in the nifedipine group than in the control group (angiographically). Nevertheless, cardiovascular mortality was larger in the nifedipine group. In 40 suggested that long acting dihydropyridine could decrease the incidence of coronary events. This study has been prolonged for 5 more years in order to calibrate adequately the side effects. In the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) 41 40 000 patients have been followed. In this study, amlodipine is the CCBs used in combination with antilipidic therapy (statins). The results are expected to be published in 2001. The Stanford Transplant Coronary Artery Disease (Diltiazem Trial) reported some protection against atherosclerosis in heart recipient patients. 42 Recently, Schweizer et al 43 published a study about verapamil and restenosis post-angioplasty. The results show that verapamil is able to curb the restenosis process. This is in agreement with previous reports. 44 Nordil 45 and Sys-China 46 studies are still in progress and some results are expected after the year 2000. Both studies are using diltiazem. Finally, although the principal results of Verapamil in Hypertension and Atherosclerosis Study (VHAS) have been published, further analysis is due showing a positive action of verapamil on carotid lessions. 47 In conclusion, ectopic calcium is a crucial step in the atherosclerotic process. CCBs are capable in diminishing calcium deposition. However, the exact mechanism is under active investigation.
11 Paradoxically, this anti-atherogenic effect is not synergistic with the antihypertensive effect to diminish cardiovascular events, particularly those related to atherosclerosis. Indeed, for some researchers, CCBs may not have a clear indication for patients with coronary artery disease. 14, 48 Other investigators consider CCBs as very safe drugs in these patients. 36 Further clinical studies are needed to completely elucidate this issue. vasoconstructor, and antiatherosclerotic effects of calcium antagonist in animal models of atherosclerosis. 
